Zogenix (ZGNX) Receives Price Target

Zogenix (ZGNX) : The highest short term price target forecast on Zogenix (ZGNX) is $28 and the lowest target price is $10. A total of 4 equity analysts are currently covering the company. The average price of all the analysts is $20.5 with a standard deviation of $9.

Zogenix (ZGNX) has an average broker rating of 1.5, which is interpreted as a Strong Buy, as rated by 4 equity analysts. Nonetheless, 3 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 1 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold.


Zogenix (NASDAQ:ZGNX): The stock opened at $8.78 on Thursday but the bulls could not build on the opening and the stock topped out at $8.78 for the day. The stock traded down to $8.01 during the day, due to lack of any buying support eventually closed down at $8.18 with a loss of -6.19% for the day. The stock had closed at $8.72 on the previous day. The total traded volume was 111,922 shares.

Zogenix, Inc. (Zogenix) is a pharmaceutical company, which is engaged in development and commercialization of therapies for people with central nervous system (CNS) disorders. The Company focuses on the areas of pain, epilepsy and schizophrenia. It is engaged in the development of Relday, a product candidate for the treatment of schizophrenia. The Company develops ZX007, an abuse-deterrent tablet formulation of single entity, extended-release hydrocodone. The Company commercializes Sumavel DosePro (sumatriptan injection), a needle-free delivery system. Sumavel DosePro offers the administration of sumatriptan for the acute treatment of migraine and cluster headache. The Company sells Sumavel DosePro to wholesale pharmaceutical distributors, pharmacies and hospitals.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.